QJQifang Jin

Qifang Jin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qifang Jin has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Ke Shi

    Department of Ophthalmology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China

    1 shared publication
  • Leifeng Chen

    Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China

    1 shared publication
  • Qian Wang

    Ophthalmic Center, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China

    1 shared publication
  • Shiqi Qin

    Ophthalmic Center, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China

    1 shared publication
  • Weiqi Wu

    Ophthalmic Center, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China

    1 shared publication
  • Wenfeng He

    Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China

    1 shared publication

Latest Publications

  • Application of photoresponsive materials in ophthalmology

    by Qian Wang, Yanxia Li, Weiqi Wu, Shiqi Qin, Zhiqi Xiong, Qifang Jin, Yu Xiong

  • Open Access

    MicroRNA‑101‑3p inhibits proliferation in retinoblastoma cells by targeting EZH2 and HDAC9

    by Qifang Jin, Wenfeng He, Leifeng Chen, Yang Yang, Ke Shi, Zhipeng You

    Retinoblastoma is the most frequent intraocular malignant tumor type to occur in childhood. MicroRNA (miR)‑101‑3p has been reported to function as a tumor suppressor in various types of cancer. However, the biological function and underlying mechanisms of miR‑101‑3p in retinoblastoma are largely unknown. In the present study, it was identified that miR‑101‑3p was downregulated in retinoblastoma. MTT and flow cytometry assays demonstrated that ectopic overexpression of miR‑101‑3p significantly inhibited cell viability and cell cycle progression in WERI‑Rb‑1 and Y79 cells. In vivo mouse experiments further confirmed the anti‑proliferative role of miR‑101‑3p in retinoblastoma. Additionally, predictions with TargetScan software indicated that the 3'‑untranslated regions of enhancer of zeste homolog 2 (EZH2) and histone deacetylase (HDAC9) mRNAs are targeted by miR‑101‑3p. Accordingly, a dual luciferase reporter gene assay demonstrated that miR‑101‑3p directly targeted EZH2 and HDAC9 to suppress the proliferation of retinoblastoma cells. Meanwhile, the restoration of EZH2 or HDAC9 expression countered the anti‑proliferative effect of miR‑101‑3p on WERI‑Rb‑1 and Y79 cells. Collectively, these data highlight the role of miR‑101‑3p in the tumorigenesis of retinoblastoma, and indicate its suitability as a novel therapeutic target.